Evidence map›Paper›PMID 39889882›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2025

Small extracellular vesicles (sEVs) in pancreatic cancer progression and diagnosis.

Reaid Hasan, Zhen Zhao, Yuanke Li, Yanli Liu, Yuanyuan Zhang, Kun Cheng

Abstract readReview
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Reaid HasanDivision of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA.
Zhen ZhaoDivision of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA.
Yuanke LiDivision of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA.
Yanli LiuDivision of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA.
Yuanyuan ZhangInstitute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA.
Kun ChengDivision of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA. Electronic address: chengkun@umkc.edu.

Funding

Development of a targeted delivery platform for checkpoint inhibitorsR01CA231099 · NCI · UNIVERSITY OF MISSOURI KANSAS CITY · PI CHENG, KUN · 2018 to 2022
$1.8M
Normalizing PDAC stroma with PCBP2 siRNA nanoparticles to improve the antitumor activity of chemotherapy and immunotherapyR01CA271592 · NCI · UNIVERSITY OF MISSOURI KANSAS CITY · PI Kun Cheng · 2023 to 2026
$1.5M
NCI NIH HHS R01 CA231099NCI NIH HHS R01 CA271592
6 · The paper itself

Abstract

Pancreatic cancer is one of the most aggressive malignancies with poor prognostic outcomes, necessitating the exploration of novel biomarkers and therapeutic targets for early detection and effective treatment. Small extracellular vesicles (sEVs) secreted by cells, have gained considerable attention in cancer research due to their role in intercellular communication and their potential as non-invasive biomarkers. This review focuses on the role of sEVs in the progression of pancreatic cancer and their application as biomarkers. We delve into the biogenesis, composition, and functional implications of sEVs in pancreatic tumor biology, emphasizing their involvement in processes such as tumor growth, metastasis, immune modulation, and chemotherapy resistance. In addition, we discuss the challenges in isolating and characterizing sEVs. The review also highlights recent advances in the utilization of sEV-derived biomarkers for the early diagnosis, prognosis, and monitoring of pancreatic cancer. By synthesizing the latest findings, we aim to underscore the significance of sEVs in pancreatic cancer and their potential to revolutionize patient management through improved diagnostics and targeted therapies.

Indexed as

Extracellular VesiclesPancreatic NeoplasmsAnimalsBiomarkers, TumorDisease ProgressionHumansBiomarkers, TumorBiomarkerCancer associated fibroblastCancer stem cellsDrug deliveryExosomePancreatic cancersEV

Identifiers

PMID39889882
PMCPMC11908897

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.